Bayer Aktiengesellschaft (BAYER) Fair Value & Analysis
Healthcare · HU · Market cap 12.9T HUF
Fair value as of: Jun 24, 2026
From 14 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from 16,785 HUF to 16,884 HUF (+0.6%) since Jun 23, 2026. Share price +31.6% over the past month.
Price vs Fair Value (12 months)
12‑month range 6,372 HUF – 14,895 HUF · fair‑value band 11,963 HUF – 30,000 HUF · the 13,605 HUF price screens below the 16,884 HUF fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Bayer Aktiengesellschaft (BAYER) currently trades at 13,605 HUF, while our model-based Fair Value estimate is 16,884 HUF — implying the stock looks roughly 24.1% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, Bayer Aktiengesellschaft generated revenue of 45.2B HUF at a net margin of -4.8%. Revenue declined 2.4% year over year. It earns a return on equity of -6.9%. Net debt stands at 28.5B HUF. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as custo…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bayer Aktiengesellschaft reported revenue of 45.6B HUF in FY2025 versus 44.1B HUF in FY2021, a compound +0.8%/yr. Reported net income was −3.6B HUF in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bayer Aktiengesellschaft (BAYER) undervalued?
What is the fair value of BAYER?
What is the quality score of BAYER?
What is the revenue of Bayer Aktiengesellschaft (BAYER)?
What is the net profit margin of BAYER?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.